Deciding whether to start hormone therapy during the menopause transition, the life phase that's the bookend to puberty and ...

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...

Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo's CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 ...

The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...